Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1993 Dec;48(12):1205–1210. doi: 10.1136/thx.48.12.1205

Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects.

B Dahlén 1, D J Margolskee 1, O Zetterström 1, S E Dahlén 1
PMCID: PMC464969  PMID: 8303624

Abstract

BACKGROUND--The cysteinyl leukotrienes (LTC4, LTD4, and LTE4) have been shown to mediate airway obstruction evoked by several factors which trigger asthmatic reactions--for example, allergen and exercise. Accordingly, drugs which block the action or formation of these leukotrienes are being evaluated as a new treatment of asthma. Elevated production of leukotrienes has been reported in asthmatic subjects who are intolerant to aspirin and related nonsteroidal anti-inflammatory drugs. In this study the influence of the specific leukotriene receptor antagonist MK-0679 was tested on basal airway function in asthmatic patients with documented aspirin intolerance. METHODS--The eight subjects in the study had a mean baseline FEV1 of 78% predicted (range 58-99%) and six required treatment with inhaled glucocorticosteroids (400-1200 micrograms budesonide/beclomethasone daily). On two separate days the subjects received either 825 mg MK-0679 or placebo, orally in a double blind, randomised, crossover design. RESULTS--The leukotriene antagonist MK-0679 caused bronchodilation which lasted for at least nine hours. The average peak improvement in FEV1 was 18% above the predrug baseline, but the bronchodilator response varied between 34% and 5% and was found to correlate strongly with the severity of asthma and aspirin sensitivity. CONCLUSIONS--The findings indicate that ongoing leukotriene production may be one cause of persistent airway obstruction in aspirin sensitive asthmatic subjects and that they may benefit from treatment with a leukotriene receptor antagonist.

Full text

PDF
1206

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arm J. P., O'Hickey S. P., Spur B. W., Lee T. H. Airway responsiveness to histamine and leukotriene E4 in subjects with aspirin-induced asthma. Am Rev Respir Dis. 1989 Jul;140(1):148–153. doi: 10.1164/ajrccm/140.1.148. [DOI] [PubMed] [Google Scholar]
  2. Björck T., Dahlén S. E. Leukotrienes and histamine mediate IgE-dependent contractions of human bronchi: pharmacological evidence obtained with tissues from asthmatic and non-asthmatic subjects. Pulm Pharmacol. 1993 Mar;6(1):87–96. doi: 10.1006/pulp.1993.1012. [DOI] [PubMed] [Google Scholar]
  3. Christie P. E., Tagari P., Ford-Hutchinson A. W., Charlesson S., Chee P., Arm J. P., Lee T. H. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis. 1991 May;143(5 Pt 1):1025–1029. doi: 10.1164/ajrccm/143.5_Pt_1.1025. [DOI] [PubMed] [Google Scholar]
  4. Dahlén B., Kumlin M., Margolskee D. J., Larsson C., Blomqvist H., Williams V. C., Zetterström O., Dahlén S. E. The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics. Eur Respir J. 1993 Jul;6(7):1018–1026. [PubMed] [Google Scholar]
  5. Dahlén S. E., Hansson G., Hedqvist P., Björck T., Granström E., Dahlén B. Allergen challenge of lung tissue from asthmatics elicits bronchial contraction that correlates with the release of leukotrienes C4, D4, and E4. Proc Natl Acad Sci U S A. 1983 Mar;80(6):1712–1716. doi: 10.1073/pnas.80.6.1712. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dahlén S. E., Hedqvist P., Hammarström S., Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature. 1980 Dec 4;288(5790):484–486. doi: 10.1038/288484a0. [DOI] [PubMed] [Google Scholar]
  7. Drazen J. M., O'Brien J., Sparrow D., Weiss S. T., Martins M. A., Israel E., Fanta C. H. Recovery of leukotriene E4 from the urine of patients with airway obstruction. Am Rev Respir Dis. 1992 Jul;146(1):104–108. doi: 10.1164/ajrccm/146.1.104. [DOI] [PubMed] [Google Scholar]
  8. Finnerty J. P., Wood-Baker R., Thomson H., Holgate S. T. Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):746–749. doi: 10.1164/ajrccm/145.4_Pt_1.746. [DOI] [PubMed] [Google Scholar]
  9. Friedman B. S., Bel E. H., Buntinx A., Tanaka W., Han Y. H., Shingo S., Spector R., Sterk P. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev Respir Dis. 1993 Apr;147(4):839–844. doi: 10.1164/ajrccm/147.4.839. [DOI] [PubMed] [Google Scholar]
  10. Gaddy J. N., Margolskee D. J., Bush R. K., Williams V. C., Busse W. W. Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma. Am Rev Respir Dis. 1992 Aug;146(2):358–363. doi: 10.1164/ajrccm/146.2.358. [DOI] [PubMed] [Google Scholar]
  11. Holroyde M. C., Altounyan R. E., Cole M., Dixon M., Elliott E. V. Bronchoconstriction produced in man by leukotrienes C and D. Lancet. 1981 Jul 4;2(8236):17–18. doi: 10.1016/s0140-6736(81)90254-3. [DOI] [PubMed] [Google Scholar]
  12. Hui K. P., Barnes N. C. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet. 1991 May 4;337(8749):1062–1063. doi: 10.1016/0140-6736(91)91709-4. [DOI] [PubMed] [Google Scholar]
  13. Israel E., Dermarkarian R., Rosenberg M., Sperling R., Taylor G., Rubin P., Drazen J. M. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med. 1990 Dec 20;323(25):1740–1744. doi: 10.1056/NEJM199012203232505. [DOI] [PubMed] [Google Scholar]
  14. Israel E., Dermarkarian R., Rosenberg M., Sperling R., Taylor G., Rubin P., Drazen J. M. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med. 1990 Dec 20;323(25):1740–1744. doi: 10.1056/NEJM199012203232505. [DOI] [PubMed] [Google Scholar]
  15. Jones T. R., Zamboni R., Belley M., Champion E., Charette L., Ford-Hutchinson A. W., Frenette R., Gauthier J. Y., Leger S., Masson P. Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol. 1989 Jan;67(1):17–28. doi: 10.1139/y89-004. [DOI] [PubMed] [Google Scholar]
  16. Kidney J. C., Ridge S. M., Chung K. F., Barnes P. J. Inhibition of platelet-activating factor-induced bronchoconstriction by the leukotriene D4 receptor antagonist ICI 204,219. Am Rev Respir Dis. 1993 Jan;147(1):215–217. doi: 10.1164/ajrccm/147.1.215. [DOI] [PubMed] [Google Scholar]
  17. Kips J. C., Joos G. F., De Lepeleire I., Margolskee D. J., Buntinx A., Pauwels R. A., Van der Straeten M. E. MK-571, a potent antagonist of leukotriene D4-induced bronchoconstriction in the human. Am Rev Respir Dis. 1991 Sep;144(3 Pt 1):617–621. doi: 10.1164/ajrccm/144.3_Pt_1.617. [DOI] [PubMed] [Google Scholar]
  18. Knapp H. R. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med. 1990 Dec 20;323(25):1745–1748. doi: 10.1056/NEJM199012203232506. [DOI] [PubMed] [Google Scholar]
  19. Knapp H. R., Sladek K., Fitzgerald G. A. Increased excretion of leukotriene E4 during aspirin-induced asthma. J Lab Clin Med. 1992 Jan;119(1):48–51. [PubMed] [Google Scholar]
  20. Kumlin M., Dahlén B., Björck T., Zetterström O., Granström E., Dahlén S. E. Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics. Am Rev Respir Dis. 1992 Jul;146(1):96–103. doi: 10.1164/ajrccm/146.1.96. [DOI] [PubMed] [Google Scholar]
  21. Lewis R. A., Austen K. F., Soberman R. J. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med. 1990 Sep 6;323(10):645–655. doi: 10.1056/NEJM199009063231006. [DOI] [PubMed] [Google Scholar]
  22. Manning P. J., Watson R. M., Margolskee D. J., Williams V. C., Schwartz J. I., O'Byrne P. M. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. N Engl J Med. 1990 Dec 20;323(25):1736–1739. doi: 10.1056/NEJM199012203232504. [DOI] [PubMed] [Google Scholar]
  23. Manso G., Baker A. J., Taylor I. K., Fuller R. W. In vivo and in vitro effects of glucocorticosteroids on arachidonic acid metabolism and monocyte function in nonasthmatic humans. Eur Respir J. 1992 Jun;5(6):712–716. [PubMed] [Google Scholar]
  24. Rasmussen J. B., Eriksson L. O., Margolskee D. J., Tagari P., Williams V. C., Andersson K. E. Leukotriene D4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol. 1992 Aug;90(2):193–201. doi: 10.1016/0091-6749(92)90071-9. [DOI] [PubMed] [Google Scholar]
  25. Samter M., Beers R. F., Jr Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med. 1968 May;68(5):975–983. doi: 10.7326/0003-4819-68-5-975. [DOI] [PubMed] [Google Scholar]
  26. Samuelsson B., Dahlén S. E., Lindgren J. A., Rouzer C. A., Serhan C. N. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science. 1987 Sep 4;237(4819):1171–1176. doi: 10.1126/science.2820055. [DOI] [PubMed] [Google Scholar]
  27. Sebaldt R. J., Sheller J. R., Oates J. A., Roberts L. J., 2nd, FitzGerald G. A. Inhibition of eicosanoid biosynthesis by glucocorticoids in humans. Proc Natl Acad Sci U S A. 1990 Sep;87(18):6974–6978. doi: 10.1073/pnas.87.18.6974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Smith L. J., Geller S., Ebright L., Glass M., Thyrum P. T. Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI 204,219. Am Rev Respir Dis. 1990 Apr;141(4 Pt 1):988–992. doi: 10.1164/ajrccm/141.4_Pt_1.988. [DOI] [PubMed] [Google Scholar]
  29. Snyder D. W., Giles R. E., Keith R. A., Yee Y. K., Krell R. D. In vitro pharmacology of ICI 198,615: a novel, potent and selective peptide leukotriene antagonist. J Pharmacol Exp Ther. 1987 Nov;243(2):548–556. [PubMed] [Google Scholar]
  30. Taylor G. W., Taylor I., Black P., Maltby N. H., Turner N., Fuller R. W., Dollery C. T. Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet. 1989 Mar 18;1(8638):584–588. doi: 10.1016/s0140-6736(89)91611-5. [DOI] [PubMed] [Google Scholar]
  31. Taylor I. K., O'Shaughnessy K. M., Fuller R. W., Dollery C. T. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet. 1991 Mar 23;337(8743):690–694. doi: 10.1016/0140-6736(91)90277-v. [DOI] [PubMed] [Google Scholar]
  32. Tocco D. J., deLuna F. A., Duncan A. E., Hsieh J. H., Lin J. H. Interspecies differences in stereoselective protein binding and clearance of MK-571. Drug Metab Dispos. 1990 Jul-Aug;18(4):388–392. [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES